Dec 1, 2011
By:
Reflector
The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
|
Aug 1, 2011
By:
Reflector
HTAs are gridlocked by diverse national requirements, a lack of alignment on processes, and even on the value of their outcomes.
|
Jul 1, 2011
By:
Reflector
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
|
Jun 1, 2011
By:
Reflector
Why has the EU still not managed to update its rules on information about medicines?
|
May 1, 2011
By:
Reflector
The EU is largely powerless when it comes to policies over pricing and reimbursement
|
Apr 1, 2011
By:
Reflector
EU leadership on pharma policy leaves many wondering of the right man is at the helm
|
Oct 1, 2010
By:
Reflector
A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers
|
Nov 2, 2009
By:
Reflector
Reflector reports on how the European pharma commitees and national associations are trying to shape the upcoming pharmaceutical package through informal
|
Aug 25, 2009
By:
Reflector
The presence of a high-flying Obama administration insider at the upcoming Swedish life sciences summit is just one indication of the seriousness with which the country taking its EU presidency.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
